Delivery Order SPE2DB20D1110-SPE2DB25FK09T
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,649.50 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on August 20, 2025, with completion scheduled for August 21, 2025. This non-set-aside contract employs firm fixed pricing and represents a direct fulfillment order under AmerisourceBergen's existing contract vehicle with the DLA. The work will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $10,308.12 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Eliquis 5 mg tablets (60-count packages). This is a firm fixed price, non-set-aside contract with a completion date of July 22, 2025, and performance location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a relatively small transaction within the company's extensive federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $14,153.62 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed price pricing and represents a child delivery order under a larger contract vehicle. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $34,772.20 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) valued at $11,836.46. This firm fixed-price delivery order, which must be completed by April 22, 2025, represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The award utilized no set-aside provisions and was competitively awarded, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Eliquis 5 mg tablets (60-count units) valued at $14,873.42 under a firm fixed-price contract. This non-set-aside delivery order represents a routine pharmaceutical procurement supporting federal medical supply requirements, with performance to be completed by July 21, 2025, and fulfillment from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at approximately $71,000 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on March 10, 2025, with completion scheduled for March 11, 2025. This non-set-aside, competitively awarded contract reflects firm fixed pricing and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $95,172.85 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on August 26, 2025, with completion targeted for August 27, 2025. This competitive award, issued under firm fixed pricing terms, supports federal medical procurement needs through AmerisourceBergen's established supply chain. The contract specifies performance from the vendor's location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $17,221.27 to AmerisourceBergen Drug Corp for 60-count packages of Eliquis 5 mg tablets, with an ultimate completion date of October 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The contract performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, the company's headquarters. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,385.55 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) on July 23, 2025, with completion scheduled for July 24, 2025. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement. The contract represents a small-value transaction typical of the pharmaceutical distribution services that AmerisourceBergen provides through its extensive federal...
- SPE2DB20D1110Indefinite Delivery Contract
- SPE2DB20D1110-SPE2DB25FK09TDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,290.13 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) on April 21, 2025, with completion targeted for April 22, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a direct delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The pharmaceutical will be sourced from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order operates as a child contract under AmerisourceBergen's significant Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply medications and medical commodities to military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates extensive capability in pharmaceutical distribution across multiple therapeutic domains, positioning it as a critical vendor for Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.3k | 4/21/25 |